The first and only at-home treatment for moderate to severe pediatric CD
Treatment at Home

HUMIRA is the first and only treatment in its category that is FDA approved for moderate to severe pediatric CD and that can be administered at home after proper training by a health care professional.

Remission and Symptom Relief

In a clinical study, at 26 weeks, many patients on HUMIRA achieved remission and more than half of the patients experienced symptom relief. Individual results may vary.

HUMIRA is not right for everyone. Only your doctor can decide if HUMIRA is right for your child.

Download the IBD Guide

You’ll find useful information about pediatric inflammatory bowel diseases (IBD), including Crohn’s disease, and how treatment with HUMIRA may help. Bring the brochure with you to discuss with the doctor at your child’s next appointment.

*Nurse Ambassadors are provided by AbbVie and do not work under the direction of your health care professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.